A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness

Simply Wall St.05-19

AdvertisementRecent share performance and company snapshot Charles River Laboratories International (CRL) has been under pressure recently, with the stock down 18% over the past month and 5% over the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636868724?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-05-19 23:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636868724","market":"sg","top_or_hot":-1,"title":"A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementRecent share performance and company snapshot Charles River Laboratories International (CRL) has been under pressure recently, with the stock down 18% over the past month and 5% over the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-look-at-charles-river-laboratories-crl-valuation-after-rec-3\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-19 23:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-look-at-charles-river-laboratories-crl-valuation-after-rec-3><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementRecent share performance and company snapshot Charles River Laboratories International (CRL) has been under pressure recently, with the stock down 18% over the past month and 5% over the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-look-at-charles-river-laboratories-crl-valuation-after-rec-3\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1815336091.USD","symbol_name":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-look-at-charles-river-laboratories-crl-valuation-after-rec-3","article_id":"2636868724","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/a-look-at-charles-river-laboratories-crl-valuation-after-rec-3","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2636868724","pubTimestamp":1779204295,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent share performance and company snapshot\nCharles River Laboratories International (CRL) has been under pressure recently, with the stock down 18% over the past month and 5% over the past 3 months, prompting closer attention from investors.\nThe US based contract research company, which supports drug discovery and safety testing across pharmaceuticals and biotech, currently has a market value of about US$7.3b and last closed at US$149.93 per share.\nSee our latest analysis for Charles River...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4530":"医药外包概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","CRL.AU":"Comet Resources Ltd","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","CRL":"查尔斯河","BK4121":"生命科学工具和服务","BK7095":"多种金属与采矿"},"translate_title":"近期股价疲软后查尔斯河实验室(CRL)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL.AU":1.5,"CRL":1.5,"DCF":1},"content_text":"AdvertisementRecent share performance and company snapshot Charles River Laboratories International (CRL) has been under pressure recently, with the stock down 18% over the past month and 5% over the past 3 months, prompting closer attention from investors. The US based contract research company, which supports drug discovery and safety testing across pharmaceuticals and biotech, currently has a market value of about US$7.3b and last closed at US$149.93 per share. See our latest analysis for Charles River Laboratories International. Against this backdrop, the 1-year total shareholder return of 6.05% contrasts with the share price weakness. The stock has retreated sharply in recent weeks and broader momentum has faded. If this shift in sentiment has you reassessing your opportunities in healthcare and biotech, it could be a good moment to scan for other specialist growth stories through our 31 healthcare AI stocks With Charles River Laboratories International down sharply in recent months but showing a 1 year total return of 6.05%, investors may be asking whether this recent weakness indicates an undervalued entry point or if the current price already reflects expectations for future growth. Most Popular Narrative: 52.2% Undervalued According to the most followed narrative, Charles River Laboratories International’s fair value of $313.61 sits well above the last close of $149.93, which is driving fresh interest in the stock’s long term setup.  The deal effectively expands and secures access to NHP supply, highlighting how critical primate availability has become in modern drug development. In other words, this acquisition reveals one of the hidden bottlenecks in the pharmaceutical research ecosystem: the supply of non-human primates.  Read the complete narrative. Curious what kind of growth path and profitability shift would justify more than doubling today’s price? The narrative leans heavily on earnings inflection, improving margins and a future valuation multiple usually reserved for higher growth healthcare leaders. Result: Fair Value of $313.61 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this bullish setup still faces risks, including regulatory scrutiny around primate sourcing and the company’s recent multi year total returns, which may curb confidence in a rerating. Find out about the key risks to this Charles River Laboratories International narrative. Another view: DCF sends a very different signal While the user narrative sees fair value at $313.61 and labels the stock undervalued, our DCF model points the other way, with an estimated value of $78.12 per share versus the current $149.93. That gap frames a simple question for you: which story do you trust more? Look into how the SWS DCF model arrives at its fair value. CRL Discounted Cash Flow as at May 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Charles River Laboratories International for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With such a strong split between bullish and cautious views, you may want to act promptly and review the full picture yourself by weighing 3 key rewards and 1 important warning sign Looking for more investment ideas? If CRL has sparked fresh thinking about your portfolio, do not stop here; the next step is comparing it with other stocks that offer different risk and return profiles.  Target potential value opportunities by reviewing companies in the 52 high quality undervalued stocks that some investors may be overlooking. Prioritise resilience by scanning stocks in the 65 resilient stocks with low risk scores if you want steadier profiles and lower risk scores. Spot earlier stage opportunities by checking the 29 elite penny stocks with strong financials that already show stronger financial foundations than many peers.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636868724","isCrawlerRequest":true}